Moreover, our findings may provide a potential therapeutic target for HIGM2 and B cell lymphoma since the mutations that disrupt the “guiding system” cause an HIGM2-like phenotype (Fig. 7). The gene discussed is AICDA; the disease is B-cell non-Hodgkin lymphoma.